Prevalence of HIV +ve Cases With AIDS Defining Opportunistic Infections Among ART Naive Patients Attending ART Centre
Conditions:   HIV Infections;   Tuberculosis;   Candidiasis, Esophageal;   Cryptococcosis;   Leishmaniasis;   Toxoplasmosis Intervention:   Other: CD4 cell count Sponsor:   Singh, Ranjan Kumar, M.D. Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - June 20, 2019 Category: Research Source Type: clinical trials

2R2: Higher Dose Rifampin for 2 Months vs Standard Dose Rifampin for Latent TB: a 3-arm Randomized Trial.
Condition:   Latent Tuberculosis Interventions:   Drug: Rifampin double dose;   Drug: Rifampin triple dose;   Drug: Rifampin standard dose Sponsors:   McGill University;   Canadian Institutes of Health Research (CIHR) Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - June 18, 2019 Category: Research Source Type: clinical trials

2R2: Higher Dose Rifampin for 2 Months vs Standard Dose Rifampin for Latent TB.
Condition:   Latent Tuberculosis Interventions:   Drug: Rifampin double dose;   Drug: Rifampin triple dose;   Drug: Rifampin standard dose Sponsors:   McGill University;   Canadian Institutes of Health Research (CIHR) Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - June 18, 2019 Category: Research Source Type: clinical trials

2R2: Higher Dose Rifampin for 2 Months vs Standard Dose Rifampin for Latent TB: a 3-arm Randomized Trial.
Condition:   Latent Tuberculosis Interventions:   Drug: Rifampin double dose;   Drug: Rifampin triple dose;   Drug: Rifampin standard dose Sponsors:   McGill University;   Canadian Institutes of Health Research (CIHR) Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - June 18, 2019 Category: Research Source Type: clinical trials

Safety and Efficacy of High Dose Rifampicin in Tuberculosis (TB)-HIV Co-infected Patients on Efavirenz- or Dolutegravir-based Antiretroviral Therapy
Condition:   Tuberculosis Intervention:   Drug: Rifampin 300 Mg Oral Capsule Sponsor:   Makerere University Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - June 11, 2019 Category: Research Source Type: clinical trials

FDA Advisory Committee Votes Favorably on the Question of the Effectiveness and Safety of Pretomanid in Combination with Bedaquiline and Linezolid for Treatment of Highly Drug-Resistant Forms of Tuberculosis
NEW YORK (June 6, 2019)—TB Alliance announced today that the U.S. Food and Drug Administration (FDA) Antimicrobial Drugs Advisory Committee voted (14 yes, 4 no, 0 abstain) that there is substantial evidence of the effectiveness and sufficient... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - June 6, 2019 Category: Pharmaceuticals Source Type: clinical trials

Assessing the Ability of the T-SPOT ®.TB Test (IQ)
Condition:   Tuberculosis Intervention:   Sponsor:   Oxford Immunotec Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - June 4, 2019 Category: Research Source Type: clinical trials